Amgen [AMGN] vs Johnson & Johnson [JNJ] Detailed Stock Comparison

Amgen Inc.

NASDAQ
Loading...

Johnson & Johnson

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amgen Inc. wins in 10 metrics, Johnson & Johnson wins in 11 metrics, with 0 ties. Johnson & Johnson appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amgen Inc. Johnson & Johnson Better
P/E Ratio (TTM) 24.22 20.49 Johnson & Johnson
Price-to-Book Ratio 21.46 6.68 Johnson & Johnson
Debt-to-Equity Ratio 640.28 60.50 Johnson & Johnson
PEG Ratio 0.22 0.42 Amgen Inc.
EV/EBITDA 13.97 16.84 Amgen Inc.
Profit Margin (TTM) 20.98% 21.83% Johnson & Johnson
Operating Margin (TTM) 30.55% 26.72% Amgen Inc.
EBITDA Margin (TTM) 30.55% 26.72% Amgen Inc.
Return on Equity 106.10% 32.87% Amgen Inc.
Return on Assets (TTM) 7.93% 13.46% Johnson & Johnson
Free Cash Flow (TTM) $8.10B $19.31B Johnson & Johnson
Dividend Yield 3.30% 2.09% Amgen Inc.
1-Year Return 20.32% 53.32% Johnson & Johnson
Price-to-Sales Ratio (TTM) 5.06 5.66 Amgen Inc.
Enterprise Value $232.21B $574.25B Johnson & Johnson
EV/Revenue Ratio 6.32 5.96 Johnson & Johnson
Gross Profit Margin (TTM) 69.84% 67.56% Amgen Inc.
Revenue per Share (TTM) $68 $40 Amgen Inc.
Earnings per Share (Diluted) $14.24 $11.04 Amgen Inc.
Beta (Stock Volatility) 0.47 0.33 Johnson & Johnson
Short % of Float 2.60% 1.03% Johnson & Johnson

Amgen Inc. vs Johnson & Johnson Stock Performance Analysis

Loading Price Chart...

AMGN
JNJ

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amgen Inc.-1.31%1.39%7.42%-4.29%7.75%6.99%
Johnson & Johnson-2.16%1.51%3.95%-3.10%10.03%13.65%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amgen Inc.20.32%54.66%48.82%137.40%512.31%431.58%
Johnson & Johnson53.32%46.67%48.70%108.58%263.36%290.52%

Performance & Financial Health Analysis: Amgen Inc. vs Johnson & Johnson

MetricAMGNJNJ
Market Information
Market Cap i$187.93B$555.84B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i2,431,7538,370,566
90 Day Avg. Volume i2,596,2917,752,965
Last Close$350.53$235.66
52 Week Range$267.83 - $391.29$149.04 - $251.71
% from 52W High-10.42%-6.38%
All-Time High$391.29 (Mar 02, 2026)$251.71 (Mar 02, 2026)
% from All-Time High-10.42%-6.38%
Growth Metrics
Quarterly Revenue Growth0.09%0.10%
Quarterly Earnings Growth1.13%-0.52%
Financial Health
Profit Margin (TTM) i0.21%0.22%
Operating Margin (TTM) i0.31%0.27%
Return on Equity (TTM) i1.06%0.33%
Debt to Equity (MRQ) i640.2860.50
Cash & Liquidity
Book Value per Share (MRQ)$16.07$33.87
Cash per Share (MRQ)$16.94$8.34
Operating Cash Flow (TTM) i$9.96B$22.21B
Levered Free Cash Flow (TTM) i$7.50B$43.47B
Dividends
Last 12-Month Dividend Yield i3.30%2.09%
Last 12-Month Dividend i$12.18$5.20

Valuation & Enterprise Metrics Analysis: Amgen Inc. vs Johnson & Johnson

MetricAMGN (Apr 24, 2026)JNJ (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i24.2220.49
Forward P/E i14.7717.80
PEG Ratio i0.220.42
Price to Sales (TTM) i5.065.66
Price to Book (MRQ) i21.466.68
Market Capitalization
Market Capitalization i$187.93B$555.84B
Enterprise Value i$232.21B$574.25B
Enterprise Value Metrics
Enterprise to Revenue i6.325.96
Enterprise to EBITDA i13.9716.84
Risk & Other Metrics
Beta i0.470.33
Book Value per Share (MRQ) i$16.07$33.87

Financial Statements Comparison: Amgen Inc. vs Johnson & Johnson

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMGN (2025)JNJ (2025)
Revenue/Sales i36.75B94.19B
Cost of Goods Sold i12.04B30.26B
COGS % of Revenue i32.8%32.1%
Gross Profit i24.71B63.94B
Gross Margin i67.2%67.9%
Research & Development i7.27B14.67B
Operating Income (EBIT) i9.08B25.60B
Operating Margin i24.7%27.2%
EBITDA i16.90B35.16B
EBITDA Margin i46.0%37.3%
Pre-Tax Income i8.98B32.58B
Pre-Tax Income % of Revenue i24.4%34.6%
Income Tax i1.27B5.78B
Income Tax % of Revenue i3.4%6.1%
Net Income (Profit) i7.71B26.80B
Profit Margin i21.0%28.5%

Balance Sheet & Liquidity Metrics

MetricAMGN (2025)JNJ (2025)
Cash & Equivalents i9.13B19.71B
Total Current Assets i29.06B55.62B
Total Current Assets % of Revenue i79.1%59.1%
Total Current Liabilities i25.49B54.13B
Total Current Liabilities % of Revenue i69.4%57.5%
Long-Term Debt i50.01B39.44B
Long-Term Debt % of Revenue i136.1%41.9%
Total Shareholders Equity i8.66B81.54B
Retained Earnings i-25.11BN/A
Retained Earnings % of Revenue i-68.3%0.0%
Property, Plant & Equipment i5.22B0

Cash Flow Statement Comparison

MetricAMGN (2025)JNJ (2025)
Operating Cash Flow i10.51B22.21B
Operating Cash Flow % of Revenue i28.6%23.6%
Capital Expenditures i-1.86B-4.83B
Free Cash Flow i8.10B19.31B
FCF Margin i22.0%20.5%
Debt Repayment i-5.00B-14.09B
Common Stock Repurchase i0-5.95B

Short Interest & Institutional Ownership Analysis

MetricAMGNJNJ
Shares Short i13.98M22.27M
Short Ratio i5.432.90
Short % of Float i2.60%1.03%
Shares Outstanding i538.80M2.41B
Float Shares i537.62M2.41B
% Held by Insiders i0.22%0.06%
% Held by Institutions i85.36%75.84%
% Held by Public i14.42%24.10%

Dividend Analysis & Yield Comparison: Amgen Inc. vs Johnson & Johnson

MetricAMGNJNJ
Last 12-Month Dividend i$12.18$5.20
Last 12-Month Dividend Yield i3.30%2.09%
3-Year Avg Annual Dividend i$9.98$4.97
3-Year Avg Dividend Yield i0.77%0.74%
3-Year Total Dividends i$29.95$14.92
Ex-Dividend DateMay 15, 2026Feb 24, 2026